Cardiol Therapeutics (CRDL) Net Cash Flow (2020 - 2026)

Cardiol Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• Quarterly Net Cash Flow rose 187.95% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 172.93% YoY) and the FY2025 annual result came in at -$6.0 million, down 33.83% from the prior year.
• Net Cash Flow was $4.4 million for Q1 2026 at Cardiol Therapeutics, down from $7.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $9.4 million in Q4 2024 and bottomed at -$9.3 million in Q4 2022.
• A 5-year average of -$2.7 million and a median of -$4.0 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 362.27% — and 2024, when it soared 296.6%.
• Cardiol Therapeutics' Net Cash Flow stood at -$9.3 million in 2022, then surged by 48.68% to -$4.8 million in 2023, then surged by 296.6% to $9.4 million in 2024, then retreated by 21.04% to $7.4 million in 2025, then tumbled by 40.53% to $4.4 million in 2026.
• Business Quant data shows CRDL's Net Cash Flow at $4.4 million in Q1 2026, $7.4 million in Q4 2025, and -$5.0 million in Q3 2025.